XOMA Royalty (XOMA) EBITDA (2011 - 2026)
XOMA Royalty (XOMA) reported EBITDA of -$477000.0 for Q1 2026, down 108.04% on a YoY basis from $5.9 million in Q1 2025, and down 121.83% sequentially from $2.2 million in Q4 2025.
XOMA Royalty (XOMA) EBITDA (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of EBITDA data on file, last reported at -$477000.0 in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 108.04% year-over-year to -$477000.0; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (up 145.3% YoY), and the FY2025 full-year result was $11.4 million, up 128.51% from the prior year.
- EBITDA retreated to -$477000.0 in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $5.9 million in Q1 2025 to a low of -$19.9 million in Q4 2023.
- A 5-year average of -$5.4 million and a median of -$5.9 million in 2023 frame the typical range for EBITDA.
- Across the five-year window, EBITDA slumped 392.49% in 2023 and soared 184.72% in 2025, its largest moves.
- Tracing XOMA's EBITDA over 5 years: stood at -$6.2 million in 2022, then tumbled by 221.0% to -$19.9 million in 2023, then surged by 63.62% to -$7.3 million in 2024, then surged by 130.13% to $2.2 million in 2025, then slumped by 121.83% to -$477000.0 in 2026.
- Business Quant data shows XOMA's EBITDA at -$477000.0 in Q1 2026, $2.2 million in Q4 2025, and $4.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -477,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -477,000.00 |
| Dec 31, 2025 | 2.19 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | -7.25 Mn |
| Sep 30, 2024 | -15.64 Mn |
| Jun 30, 2024 | -10.08 Mn |
| Mar 31, 2024 | -7.00 Mn |
| Dec 31, 2023 | -19.93 Mn |
| Sep 30, 2023 | -5.79 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -10.17 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | 30.37 Mn |
| Sep 30, 2021 | -3.35 Mn |
| Jun 30, 2021 | -3.06 Mn |
| Mar 31, 2021 | -6.43 Mn |